Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study

Home blood pressure measurement, telemonitoring... | HRB Open Research dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); const cookieDomain = window.location.hostname; const tld = buildTLD(); function buildTLD() { const domainParts = cookieDomain.split('.'); while (domainParts.length > 2) { domainParts.shift(); } return domainParts.join('.'); } function deleteCookie(cookieName) { if (!cookieName) { return; } const cookiePath = (cookieName.startsWith('retraction_warning_') || cookieName.startsWith('version_warning_')) ? '/articles/' + cookieName : '/'; // Yes, these three slightly different ways to try and remove cookies are necessary document.cookie = cookieName + '=; path=' + cookiePath + '; domain=' + cookieDomain + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; document.cookie = cookieName + '=; path=' + cookiePath + '; domain=.' + tld + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; document.cookie = cookieName + '=; path=' + cookiePath + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; } function deleteGroupCookies(group) { if (!group) { return; } const domainData = OneTrust.GetDomainData(), cookies = domainData.Groups.filter(cookieGroup => cookieGroup.OptanonGroupId === group)[0].Cookies; cookies.forEach(cookie => deleteCookie(cookie.Name)); } function OptanonWrapper() { const cookieConsentGroups = []; for (group of OneTrust.GetDomainData().Groups) { cookieConsentGroups.push(group.OptanonGroupId); } OneTrust.OnConsentChanged(function(e) { const cookieConsentActiveGroups = OnetrustActiveGroups.split(',').filter(activeGroup => activeGroup); cookieConsentGroups.forEach(group => { if (!cookieConsentActiveGroups.includes(group)) { deleteGroupCookies(group); }; }); }); } window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://hrbopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'HRB'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content HRB Open Research file_upload Submit your research search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Data Guidelines Prepublication Checks Production Process Article Processing Charges Finding Article Reviewers About How it Works For Reviewers National Steering Group Policies Glossary FAQs Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://hrbopenresearch.org/articles/8-131" }, "headline": "Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic...", "datePublished": "2025-12-16T15:11:58", "dateModified": "2025-12-16T15:11:58", "author": [ { "@type": "Person", "name": "Pádraig Synnott" }, { "@type": "Person", "name": "Kirstyn James" }, { "@type": "Person", "name": "Brian Caulfield" }, { "@type": "Person", "name": "Catherine Lynch" }, { "@type": "Person", "name": "Katrina Tobin" }, { "@type": "Person", "name": "John J McCabe" }, { "@type": "Person", "name": "Michael Marnane" }, { "@type": "Person", "name": "Peter Megyesi" }, { "@type": "Person", "name": "David J Williams" }, { "@type": "Person", "name": "Sarah Coveney" }, { "@type": "Person", "name": "Derek Hayden" }, { "@type": "Person", "name": "Tim Cassidy" }, { "@type": "Person", "name": "David Bradley" }, { "@type": "Person", "name": "Peter J Kelly" } ], "publisher": { "@type": "Organization", "name": "HRB Open Research", "logo": { "@type": "ImageObject", "url": "https://hrbopenresearch.org/img/AMP/HRB_image.png", "height": 566, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://hrbopenresearch.org/img/AMP/HRB_image.png", "height": 1200, "width": 127 }, "description": " Background Hypertension is a key risk factor for stroke, and elevated blood pressure (BP) is associated with an increased risk of recurrence following ischaemic stroke or transient ischaemic attack (TIA). European Stroke Organisation (ESO) guidelines recommend office BP reduction for secondary prevention to systolic BP (SBP) <130mmHg. However, high rates of failure to achieve guideline BP targets are reported. The benefit of SBP reduction in certain groups (eg. older patients), and to even lower levels, remains uncertain. Home blood pressure measurement with telemonitoring (HBPM-TM) is a promising strategy to improve guideline compliance, and to evaluate safety of very low SBP targets. However, few data exist on HBPM-TM after ischaemic stroke or TIA. Methods European blood Pressure Intensive Control after Stroke (EPICS)-Pilot is a prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot and feasibility clinical trial. The study compares the efficacy of HBPM-TM plus protocol-guided titration of antihypertensive medication versus usual care, to achieve guideline-based SBP targets, and to assess the safety and tolerability of intensive SBP reduction. Included patients enrolled from acute hospitals have ischaemic stroke or high-risk TIA and SBP≥130mmHg at baseline. Participants in the intervention group will return home measures via smartphone app or mail, and the study team will titrate medications according to a defined algorithm. The primary outcome will be the difference in mean SBP office measurement between the intervention and control arms at 3 months. Target recruitment is 142 patients (71 per arm). Secondary outcomes include feasibility of recruitment, retention, and feasibility and acceptability of the intervention. Safety data will be reported. Discussion HBPM-TM with medication titration may improve BP control for ischaemic stroke and TIA patients. Our trial will determine if this study design is suitable for a larger phase 3 efficacy study, as well as testing specific study tasks for feasibility. Trial registration ClinicalTrials.gov NCT04647292. Registered 20th November 2020, https://clinicaltrials.gov/study/NCT04647292. Protocol Version Number V5, 06/06/2024. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://hrbopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://hrbopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://hrbopenresearch.org/articles/8-131/v1", "name": "Home blood pressure measurement, telemonitoring and medication titration..." } } ] } Home Browse Home blood pressure measurement, telemonitoring and medication titration... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Synnott P, James K, Caulfield B et al. Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] . HRB Open Res 2025, 8 :131 ( https://doi.org/10.12688/hrbopenres.14281.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Study Protocol Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] Pádraig Synnott https://orcid.org/0000-0002-1398-8754 1-3 , Kirstyn James 1,4 , Brian Caulfield 5 , [...] Catherine Lynch 1 , Katrina Tobin 1 , John J McCabe https://orcid.org/0000-0003-2029-1303 1-3 , Michael Marnane 1-3 , Peter Megyesi https://orcid.org/0000-0002-9165-0070 5 , David J Williams https://orcid.org/0000-0002-1923-462X 1,6,7 , Sarah Coveney 1,8 , Derek Hayden 1,8 , Tim Cassidy 1,2,9 , David Bradley 1,10 , Peter J Kelly 1-3 Pádraig Synnott https://orcid.org/0000-0002-1398-8754 1-3 , Kirstyn James 1,4 , [...] Brian Caulfield 5 , Catherine Lynch 1 , Katrina Tobin 1 , John J McCabe https://orcid.org/0000-0003-2029-1303 1-3 , Michael Marnane 1-3 , Peter Megyesi https://orcid.org/0000-0002-9165-0070 5 , David J Williams https://orcid.org/0000-0002-1923-462X 1,6,7 , Sarah Coveney 1,8 , Derek Hayden 1,8 , Tim Cassidy 1,2,9 , David Bradley 1,10 , Peter J Kelly 1-3 PUBLISHED 16 Dec 2025 Author details Author details 1 Health Research Board (HRB), Stroke Clinical Trials Network Ireland (SCTNI), Dublin, Ireland 2 University College Dublin School of Medicine, Dublin, Leinster, Ireland 3 Stroke Service, Mater Misericordiae University Hospital, Dublin, Leinster, Ireland 4 Department of Geriatric Medicine, Cork University Hospital, Cork, County Cork, Ireland 5 Insight Centre for Data Analytics, University College Dublin, Dublin, Leinster, Ireland 6 Royal College of Surgeons in Ireland Faculty of Medicine and Health Sciences, Dublin, Leinster, Ireland 7 Department of Stroke Medicine, Beaumont Hospital, Dublin, Leinster, Ireland 8 Department of Geriatric and Stroke Medicine, Tallaght University Hospital, Dublin, Leinster, Ireland 9 Department of Geriatric Medicine, St Vincent's University Hospital, Dublin, Leinster, Ireland 10 Department of Neurology, St James's Hospital, Dublin, Leinster, Ireland Pádraig Synnott Roles: Investigation, Writing – Original Draft Preparation, Writing – Review & Editing Kirstyn James Roles: Writing – Review & Editing Brian Caulfield Roles: Writing – Review & Editing Catherine Lynch Roles: Project Administration, Writing – Review & Editing Katrina Tobin Roles: Project Administration, Writing – Review & Editing John J McCabe Roles: Writing – Review & Editing Michael Marnane Roles: Writing – Review & Editing Peter Megyesi Roles: Writing – Review & Editing David J Williams Roles: Writing – Review & Editing Sarah Coveney Roles: Writing – Review & Editing Derek Hayden Roles: Writing – Review & Editing Tim Cassidy Roles: Writing – Review & Editing David Bradley Roles: Writing – Review & Editing Peter J Kelly Roles: Conceptualization, Funding Acquisition, Methodology, Supervision, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background Hypertension is a key risk factor for stroke, and elevated blood pressure (BP) is associated with an increased risk of recurrence following ischaemic stroke or transient ischaemic attack (TIA). European Stroke Organisation (ESO) guidelines recommend office BP reduction for secondary prevention to systolic BP (SBP) <130mmHg. However, high rates of failure to achieve guideline BP targets are reported. The benefit of SBP reduction in certain groups (eg. older patients), and to even lower levels, remains uncertain. Home blood pressure measurement with telemonitoring (HBPM-TM) is a promising strategy to improve guideline compliance, and to evaluate safety of very low SBP targets. However, few data exist on HBPM-TM after ischaemic stroke or TIA. Methods European blood Pressure Intensive Control after Stroke (EPICS)-Pilot is a prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot and feasibility clinical trial. The study compares the efficacy of HBPM-TM plus protocol-guided titration of antihypertensive medication versus usual care, to achieve guideline-based SBP targets, and to assess the safety and tolerability of intensive SBP reduction. Included patients enrolled from acute hospitals have ischaemic stroke or high-risk TIA and SBP≥130mmHg at baseline. Participants in the intervention group will return home measures via smartphone app or mail, and the study team will titrate medications according to a defined algorithm. The primary outcome will be the difference in mean SBP office measurement between the intervention and control arms at 3 months. Target recruitment is 142 patients (71 per arm). Secondary outcomes include feasibility of recruitment, retention, and feasibility and acceptability of the intervention. Safety data will be reported. Discussion HBPM-TM with medication titration may improve BP control for ischaemic stroke and TIA patients. Our trial will determine if this study design is suitable for a larger phase 3 efficacy study, as well as testing specific study tasks for feasibility. Trial registration ClinicalTrials.gov NCT04647292. Registered 20 th November 2020, https://clinicaltrials.gov/study/NCT04647292 . Protocol Version Number V5, 06/06/2024. READ ALL READ LESS Keywords Stroke, Hypertension, telemonitoring, self-measurement, secondary prevention, home blood pressure measurement. Corresponding Author(s) Pádraig Synnott ( [email protected] ) Close Corresponding author: Pádraig Synnott Competing interests: No competing interests were disclosed. Grant information: Health Research Board [DIFA-2020-015] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2025 Synnott P et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Synnott P, James K, Caulfield B et al. Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] . HRB Open Res 2025, 8 :131 ( https://doi.org/10.12688/hrbopenres.14281.1 ) First published: 16 Dec 2025, 8 :131 ( https://doi.org/10.12688/hrbopenres.14281.1 ) Latest published: 16 Dec 2025, 8 :131 ( https://doi.org/10.12688/hrbopenres.14281.1 ) Background Approximately 1.1 million people in Europe have a stroke each year 1 . Recurrence of vascular events after stroke is a major problem, affecting almost one-third of survivors by 5 years 2 . Transient ischaemic attack (TIA) also increases risk of stroke, with a recent international study noting 6% of people with TIA suffered a stroke within 1 year 3 . Hypertension is a key risk factor for stroke. A 20mm Hg systolic or 10mm Hg diastolic increase in blood pressure (BP) is associated with an approximate doubling in first-ever stroke risk, and elevated blood pressure following stroke/TIA is associated with an increased risk of recurrence 4 , 5 . Results of clinical trials such as PROGRESS support BP lowering after ischaemic stroke to reduce recurrent stroke events 6 . The SPS3 7 , PAST BP 8 , and RESPECT 9 trials support blood pressure lowering to a target of <130mmHg for secondary prevention, whichis the current recommendation of the European Stroke Organisation (ESO) 10 , American Stroke Association 11 and National Clinical Guideline for Stroke for the UK and Ireland guidelines 12 . There are high rates of failure to achieve guideline recommended targets in clinical practice 13 – 15 . Home blood pressure measurement and telemonitoring (HBPM-TM) is a promising approach to improve BP compliance. HBPM-TM is recognised from previous studies such as TASMIN-SR 16 and TASMIN-H4 17 as being acceptable to patients, and the TASMIN-SR trial noted a significant reduction in BP at 12 months. The latest ESO guidelines note continued uncertainty over the use of out-of-office blood pressure measurements for adult patients following ischaemic stroke or TIA due to insufficient data, and recommend further research 10 . European blood Pressure Intensive Control after Stroke (EPICS) Pilot trial will recruit patients with recent stroke/high-risk TIA events with systolic BP ≥130 mmHg and randomise them to standard of care or HBPM-TM and early medication titration. The study hypothesis is that HBPM-TM with early medication titration may lead to improved BP control compared to standard of care clinical practice, where titration of medications is often done based on office-measured BPs typically at visit intervals of several months. The aims of this study are the following: 1) To evaluate the effect of the intervention on early SBP control 2) To assess the feasibility of HBPM-TM, as well as the feasibility of specific study tasks, including patient identification and retention, and remote medication titration 3) To explore the acceptability of HBPM-TM in stroke/high-risk TIA patients 4) To examine the safety of HBPM-TM and remote medication titration in stroke/high-risk TIA patients Methods and design Study design EPICS-Pilot is an investigator led prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot/feasibility clinical trial, comparing BP patient self-measurement and telemonitoring with standard of care monitoring for improved BP control after ischaemic stroke/TIA. It fulfils the non-mutually exclusive criteria for both a pilot study (testing a design for a larger trial on a smaller scale) and feasibility study (testing if specific study tasks are possible and should proceed as initially-planned) 18 , in preparation for a larger randomised trial. The intervention group are randomised to home-based BP self-measurement, telemonitoring, and medication titration, and the control group to usual care, which may incorporate office-based BP measurement, ambulatory blood pressure measurement (ABPM) or HBPM. In both arms, treating physicians are advised to target BP control based on current ESO 10 , American Stroke Association 11 and UK guidelines (target SBP <130mmHg). The primary outcome measure will be the difference in mean SBP office measurement between the intervention and control arms at 3 months. Setting and participants The study includes stable patients with SBP≥130 from 72 hours to 1 year after ischaemic stroke, or high-risk TIA ( Table 1 ), with the goal of obtaining results that will be widely-generalisable to the patient intended for inclusion in a later definitive trial, and to most patients with ischaemic stroke/TIA. Participants are recruited from outpatient clinics, or inpatient stroke units nearing time of discharge, at six acute hospitals in Ireland (4 Primary Stroke Centres, and 2 Comprehensive Stroke Centres). Table 1. Eligibility Criteria for EPICS. Inclusion Criteria Exclusion Criteria 1. Age ≥40 1. SBP <110mmHg after 3 minutes of standing or other contra-indication 2 to intensive SBP lowering in opinion of treating clinician (eg. Orthostatic symptoms, syncope or pre syncope, recurrent falls) 2. Ischaemic stroke 1 (including stroke secondary to large-artery atherosclerosis, cardio-embolism or undetermined aetiology), OR High-risk TIA 1 AND Brain CT/MRI has excluded primary intracranial haemorrhage 2. Qualifying stroke due to intracerebral haemorrhage (ICH) or other defined causes (eg. Dissection, endocarditis, other specified) 3. Living at home and independent (walking without the aid of another person, but may have some help for daily activities) 3. Severe stenosis or occlusion of large cranio-cervical artery (>70% stenosis/occlusion of cervical carotid, vertebral, or Circle of Willis artery) 4 . SBP≥130mmHg at entry (average of 2nd and 3rd measures, seated, in the same arm, after resting alone in office for 10 minutes) 4 . Unlikely to comply with study procedures due to severe or fatal comorbid illness (eg. dementia, active malignancy, severe frailty) or other factor (eg. inability to travel) 5. Qualifying event between 72 hours and 1 year of randomisation 5. Pregnancy or breastfeeding 6. Glomerular filtration rate (eGFR) greater than or equal to 50ml/min/m2 (within 3 months of randomisation 7. Medically-stable and capable of participating in a randomised trial, including home BP measures, in the opinion of the study physician 8. Willing to provide written informed consent (no surrogate consent will apply) 1. stroke includes symptoms<24 hours duration with imaging evidence of acute brain ischaemia. High-risk TIA defined as motor or speech symptoms <24 hours duration, no acute imaging evidence of infarction, and craniocervical stenosis in appropriate artery of 30–69%. 2. if a contra-indication exists to an anti-hypertensive drug class [eg. ACE inhibitors], patients will not be excluded from the trial but clinicians will be requested to prescribe an alternative antihypertensive agent) Randomisation and group allocation Patients who meet eligibility criteria and provide written informed consent are randomly allocated to one BP monitoring strategy using a web-based randomisation tool. The randomisation tool incorporates a minimisation algorithm to ensure groups are balanced for key prognostic variables affecting recurrent stroke risk, including age, time since qualifying event, history of prior stroke/TIA, and presence of high-risk markers (ischaemic heart disease, diabetes or current smoking). At randomisation, a unique participant identifier is generated for each trial participant. Assessment and follow-up schedule Baseline assessment All participants receive appropriate lifestyle and dietary advice, smoking cessation advice and antithrombotic and lipid-lowering treatment per guidelines. Co-morbid medical conditions, concomitant medications, baseline modified Rankin score, baseline cognitive assessments (Montreal Cognitive Assessment, MOCA), and baseline quality of life assessment (EQ-5D-5L) are assessed. Frailty is measured using the Rockwood Clinical Frailty Scale. Intervention arm At the Baseline Visit, patients randomised to HBPM+TM are trained in the technique of HBPM using standardized materials provided by the British and Irish Hypertension Society (BIHS). They are provided with a bluetooth-enabled licensed validated HBPM device (Omron M4), with cuff size appropriate to their arm circumference. For the first three months they are instructed to measure their BP a minimum of four times weekly (maximum once daily), and twice weekly thereafter. They take 3 consecutive measurements (separated by at least 1 minute), ideally in the morning (0600am-1200pm) or evening (1800-2400pm). BP measures are returned to their local trial team weekly for the first 3 months, and monthly thereafter. Patients have the choice of two options to communicate their BP measures to the study office: 1. Returning their readings to the clinician by manually entering their readings into the trial smartphone app, which will transmit readings directly to the research team OR 2. Mailing the written record from their BP diary to the study office. (For this they are given a BP diary for written entry of BP values and stamped addressed envelopes at their baseline visit). Face-to-face (FTF) in-person follow-up visits are conducted at 3 months, 6 months, and end of trial (12 months) (3 FTF visits over the course of the trial). Assessments for safety, recurrent events, concomitant medications, and compliance are done at all FTF visits, together with review of HBPM technique and re-training if required. Renal function is measured at 3 months. Further monitoring of renal function may be required at other time periods based on medication titration and local-site clinical judgement. Office BP measures (3 measures, seated, average of measures 2 and 3 calculated) are done. Qualitative feedback from patients on their views relating to the feasibility of home blood pressure monitoring, positive and negative aspects (eg. potential for raising health anxiety), and other study procedures is sought at each FTF visit. In addition, brief scheduled phone calls are done at months 1, 2, 8 and 10. Each of these takes approximately 15 minutes and is done by trial staff at the local participating centres, to assess for the presence of outcome events, SAEs, treatment compliance. BP medications are titrated if required. Smartphone app A dedicated smartphone app has been developed to facilitate transmission of HBPM directly to the study team. The app requires participants to manually input the readings taken using their HBPM device, which are then communicated to the clinician. Participants receive an appropriate prompt to re-measure or seek medical assistance if readings are SBP180/100). The app contains a video demonstrating the correct technique for home blood pressure monitoring. Clinicians are able to review individual BP readings on a clinician dashboard interface at the treating hospital and rapidly address home BP readings outside the intended target range. Medication titration At randomisation, participants in the intervention arm receive intensification of their antihypertensive treatment, according to the algorithm in Figure 1 . Medications are titrated at least monthly to reach a target SBP<130, based on calculation of the average SBPs of the 2nd and 3 rd home blood pressure measurements. The choice and dose of antihypertensive treatment(s) is at the discretion of the treating clinicians, with a recommended strategy of medication titration based on low-to-moderate doses of different classes of antihypertensive drugs. Medication titration continues for the duration of the trial based on home blood pressure measurements. Figure 1. Treatment algorithm for medication titration for participants in intervention arm. Control group Patients randomised to SOC are advised to attend their GP and/or hospital physician for routine office-based BP measures, as per usual care. They have a face-to-face study visit at 3 months to incorporate an office BP measure, a telephone call at 6 months, and an end-of-trial FTF visit at 12 months. Full details of the schedule of events for both participant groups are available in Table 2 . Table 2. Schedule of Events. Screening/ Baseline Follow Up Follow Up End of Trial Assessments/ Outcomes Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7 Month 8 Month 9 Month 10 Month 11 Month 12 Inclusion Exclusion Criteria x Informed Consent 1 x Clinical assessment x Blood Pressure 2 x x x x Pregnancy test 3 x Renal function test 4 x X Randomisation x Lifestyle/dietary advice x Co-morbid medical conditions check x x Concomitant medications check x x x x x x x x Modified Rankin score x x Montreal Cognitive Assessment (MOCA) x x Quality of life assessment (EQ-5D-5L) x x Rockwood Frailty Scale score x x Randomization Intervention Group 5 x x x x x x x Blood pressure diary review x x x x x x x x x x x x BP medication titration (if required) x x x x x x x x x x x x Home blood pressure technique review x x x x x x x Qualitative feedback x x x SOC 6 x x x Adverse events/ outcomes review x x x x x x x x 1 Written informed consent should be obtained before any study related procedures. 2. Patients to rest for 10 minutes alone (3 measures, seated, average of measures 2 and 3 calculated). 3. To be done on all women of childbearing potential. 4. A baseline eGFR should be checked if not done in the last 3 months. Intervention Group - renal function test at 3 months. Further monitoring of renal function may be required at other time periods based on medication titration and local-site clinical judgement. 5 Intervention Group Face to face (FTF) visits at 3, 6, and 12 months and phone visits at months 1, 2, 8 and 10months. 6 SOC FTF at 3 and 12months, including blood pressure measurement, and phone visits at 6 months. Outcome measures Primary outcome The primary outcome will be the difference in mean SBP (office-based measure, mean of 2nd and 3rd measures, same arm and cuff size, seated, after 10 minutes rest) between the intervention versus control groups, measured at 3 months. This outcome is a single over-arching feasibility measure of treatment strategy effectiveness. In randomised trials, clinical benefit of SBP reduction is proportional to the attained SBP difference between treatment arms. Secondary outcomes Secondary outcomes are outlined in Table 3 . Table 3. Secondary and Feasibility Outcomes. Secondary Outcomes 1. Difference in mean SBP (office-based measure, mean of 2nd and 3rd measures, same arm and cuff size, seated, after 10 minutes rest) between the intervention versus control groups, measured at 12 months (or last trial visit) 10. Number of dose-titrations required 2. Proportions of patients assigned to each arm successfully reaching guideline- based targets (SBP<130mmHg) at 3 months and at end of trial visit 11. Time required per follow up visit 3. Time in guideline-based target range (proportion of SBP measures <130 during trial participation) 12. Number of patients lost to follow-up 4. Time taken to reach target 13. Number of serious adverse events 5. Difference in mean diastolic blood pressure (DBP) between groups 14. Number of pre-specified adverse events (see Safety section below) 6. Change in SBP/DBP from baseline to end-of-trial 15. Change in cognition (baseline-to-end of trial) (measured by Montreal Cognitive Assessment) 7. Time to first composite major adverse cardiovascular event ([MACE] (defined as all recurrent stroke, myocardial infarction, cardiac arrest), and to each component of the composite, stratified as fatal, non-fatal and total) 16. Change in health-related quality of life (measured by EuroQoL EQ-5D-5L) (baseline-to-end of trial) 8. All-cause fatality 17. Qualitative patient feedback obtained via workshops and/or questionnaires 9. Comparison of disability in each intervention arm assessed by modified Rankin score (shift analysis and proportion with no, mild, or moderate disability, Rankin score 0–3) 18. Change in Rockwood Clinical Frailty Scale (baseline to end of trial) Feasibility Outcomes 1. Number of patients who do not complete the study due to tolerability or other issues 3. Patient acceptability of HBPM and telemonitoring 2. Ability of sites to rapidly identify eligible patients from clinics and stroke units 4. Compliance with telemonitoring and feasibility of remote (phone) visits Safety and adverse events The safety and tolerability of study interventions is evaluated and reported consistently in EPICS, including the reporting of the pre-specified adverse events outlined in Table 4 . Other events which fulfil Good Clinical Practice (GCP) guidelines as Serious (ie. Causing death, disability, hospitalisation, other important medical events, or congenital defects) are systematically monitored and reported. All Serious Adverse Events (SAEs) identified by site staff are recorded on the trial database and reported within 24 hours to the Safety Monitoring office. The sponsor Safety Monitoring team will follow these events until resolution or until the event is considered stable by the Site Investigator. Safety outcomes, including SAEs and pre-specified adverse events, will be compared between intervention and control groups. Table 4. Pre-specified adverse events. Pre-specified Adverse Events 1. Syncope (loss of consciousness, not related to seizure or cardiac event) 5. Acute kidney injury or acute renal failure 2. Stroke associated with clearly-documented hypotension 6. Serum sodium 150mmol/L 3. Falls with injury, defined as requiring hospitalisation or assessment at emergency department (SPRINT definition) 7. Serum potassium 5.5mmol/L 4. Severe dizziness, lightheadedness, or unsteadiness when standing, requiring physician assessment outside of the trial Table 4 describes pre-specified adverse events that will be monitored in the trial. Recurrent stroke includes ischaemic stroke, intracerebral haemorrhage, and subarachnoid haemorrhage. Hospitalisation is defined as “any event resulting in an overnight stay in hospital”. The following are not included in the definition of hospitalisation and do not require reporting as SAEs – Visits to clinics or day hospitals, emergency departments or other hospital day services eg minor surgical procedures; surgeries or procedures planned before randomisation but conducted after; Hospital admission for an outcome event. Acute kidney injury is defined as an Increase in serum creatinine to X1.5 times baseline, which is known or presumed to have occurred within the prior 7 days. Sample size A sample size of 142 patients (71 per arm) will provide 80% power (alpha 0.05) to detect an effect size at least of 8mmHg difference (standard deviation 17mmHg, mean SBP 127mmHg versus 135mmHg) between intensive and control arms. Statistical analysis For the primary analysis, baseline variables will be compared using t-tests or Wilcoxon tests (continuous variables) and chi-squared (categorical variables) testing. The primary outcome (difference in mean SBP) will be compared in intervention and control arms using a t-test, after verifying that the distributions fulfil assumptions of normality. Analysis of each feasibility measure will be done by examining numbers and proportions of patients compared within study arms where appropriate by chi-squared tests, supplemented by review of qualitative data as appropriate. For secondary outcomes, we will compare the time to the first occurrence of the composite vascular outcome using a log-rank test and will utilize multivariable Cox regression to test the hazard ratio of the composite vascular outcome by SBP study arm with appropriate adjustment for potential confounders depending on the number of outcome variables. Annual event rates per SBP category will be established using life-table analysis and Kaplan Meier curves with censoring for patients lost to follow-up. Other secondary outcomes and safety events will be compared using t-tests, Wilcoxon tests, or chi-squared tests as appropriate for continuous (normal or non-normal distributed) or categorical data. Data management, monitoring and auditing An electronic Case Report Form (eCRF) is used for this study. The data in the study database is pseudo-anonymised. A number is assigned to each patient which will be mapped to identifiable patient details at each hospital site only. Central data management is performed by an experienced Data Management Centre. User access will be controlled via assigned usernames and passwords, approved by the study Data Manager. The main database is hosted in a secure data centre. All sites will have remote data monitoring conducted by the Project Team, and data checked for completeness, logic, and validity, with queries sent to sites to verify data as required. Discussion Although hypertension is a well-established risk factor for recurrent stroke, blood pressure frequently remains inadequately controlled, with previous cohorts not meeting the historically recommended target of SBP <140. In Europe, the Euro-aspire study showed that only 38% of patients had controlled BP at 1 year 15 . Irish findings are similar, with Aspire-S showing only 37% control, and Irish primary-care cohort studies of stroke/TIA patients showing only one third had controlled BP 13 , 14 . Current ESO guidelines recommend BP lowering to <130 following ischaemic stroke/TIA. However, the optimal strategy to achieve this for stroke patients is not clear. ESO guidelines note continued uncertainty over the use of out-of-office BP measures and recommend further research in this area. New implementation strategies to bridge the gap between the evidence base and achieving improved hypertension control are essential. HBPM with telemonitoring has good potential, particularly in the early post stroke period, where stroke recurrence risk is high, and engagement with treatment may be improved. HBPM and self-management of BP are effective strategies for BP lowering in non-stroke patients with hypertension. The most recent individual patient-data meta-analysis of self-monitoring in hypertension also found that self-monitoring was effective at BP lowering in patients with hypertension-related multimorbidity 19 . However, for stroke patients specifically, this benefit was dependent on high-intensity co-interventions accompanying self-monitoring, including systematic medication titration by doctors, pharmacists or patients, or individually tailored support from study personnel. Low-intensity interventions such as self-monitoring with initial education, or with automated feedback or support was not associated with improved BP control. People with stroke face additional challenges in hypertension management, which may account for the requirement for high-intensity co-interventions to show the benefits of HBPM. These may include post-stroke depression, disability and cognitive impairment, which may impact both medication adherence and accessing services for medication titration. Patient concerns regarding possible adverse events due to antihypertensive medication may also be a factor, as may clinician inertia to optimise BP treatment in some cases. HBPM-TM is recognised as convenient and therefore acceptable to most patients and healthcare practitioners 16 Feasibility studies have highlighted the potential of this benefit for stroke patients using different co-intervention strategies 20 , 21 . The TASMIN5S-IRL feasibility study in high cardiovascular risk stroke and TIA patients reported that a strategy of blood pressure self-monitoring using an integrated feedback system and medication titration was feasible and acceptable to patients 20 In comparison to EPICS, TASMIN5S-IRL was based in primary care, and patients were enrolled at least one month after their qualifying event for a 3 month intervention. Titration was completed with a three-step titration plan agreed at the baseline visit. The frequency of BP measurement was also less frequent compared to EPICS, with BP measured monthly for three days (twice daily) within a 7-day period. In contrast, the EPICS trial intervention arm will incorporate BP readings 4-times weekly for the first three months, and twice-weekly thereafter. Similarly, the TASC (Telehealth After Stroke Care) feasibility study found HBPM-TM with multidisciplinary intervention for stroke patients lowered SBP at 3 months 21 . The intervention arm of this trial included HBPM with wireless transmission of readings, telenursing support, and pharmacist visits. Different co-intervention strategies may need to be tailored for specific populations, with a recent trial of HBPM-TM in Black and Hispanic Stroke patients highlighting the additional benefit of nurse case-management compared to HBTM-alone 22 . Strengths and limitations Our study has a number of strengths. EPICS-Pilot gives particular focus to the early post-stroke/TIA period where recurrence risk is highest, and aims to establish BP control in the first three months through weekly review of readings and medication titration at least monthly. The use of a defined algorithm for medication titration while allowing physician choice of antihypertensive class encourages achieving target BP based on low-to-moderate doses of different classes of antihypertensives, while mirroring current prescribing practice. The usual care group reflects contemporary “real-world” practice, and includes not just office-based BP, but ambulatory blood pressure monitoring and self-measured blood pressures as per standard care. Through the use of a smartphone app to return blood pressure readings, the study team can explore the feasibility and acceptability of mobile health technology for this purpose in a stroke population. The broad inclusion criteria will enhance external validity of the study. Limitations include the small sample size and restricted geographic setting (Ireland), which may limit generalisability to other healthcare settings. EPICS-Pilot will provide new evidence on a novel strategy of home blood pressure monitoring and telemonitoring to improve hypertension management to inform future randomised controlled trials. Ethics and consent Favourable ethical approval was obtained from The Mater Misericordiae University Hospital Research Ethics Committee on 13th December 2023 (reference 1/378/2374). All authors have consented to the publication of the research presented in this manuscript. Trial sponsor University College Dublin [email protected] List of abbreviations BP – Blood Pressure TIA – Transient Ischaemic Attack ESO – European Stroke Organisation SBP – Systolic Blood Pressure HBPM – Home Blood Pressure Measurement HBPM-TM – Home Blood Pressure Measurement and Telemonitoring ABPM - ambulatory blood pressure measurement Data availability Underlying data No data are associated with this protocol article. Reporting guidelines Zenodo: Spirit Checklist for Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study (DOI: 10.5281/zenodo.17419006 ) https://zenodo.org/records/17419006 23 . Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication). Faculty Opinions recommended References 1. Béjot Y, Bailly H, Durier J, et al. : Epidemiology of stroke in Europe and trends for the 21st century. Presse Med. 2016; 45 (12 Pt 2): e391–e398. PubMed Abstract | Publisher Full Text 2. Li L, Yiin GS, Geraghty OC, et al. : Incidence, outcome, risk factors, and long-term prognosis of cryptogenic Transient Ischaemic Attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015; 14 (9): 903–913. PubMed Abstract | Publisher Full Text | Free Full Text 3. Amarenco P, Lavallée PC, Labreuche J, et al. : One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med. 2016; 374 (16): 1533–1542. PubMed Abstract | Publisher Full Text 4. Lewington S, Clarke R, Qizilbash N, et al. : Age-specific relevance of usual Blood Pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002; 360 (9349): 1903–1913. PubMed Abstract | Publisher Full Text 5. Kaplan RC, Tirschwell DL, Longstreth WT Jr, et al. : Blood Pressure level and outcomes in adults aged 65 and older with prior ischemic stroke. J Am Geriatr Soc. 2006; 54 (9): 1309–1316. PubMed Abstract | Publisher Full Text 6. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or Transient Ischaemic Attack. Lancet. 2001; 358 (9287): 1033–1041. PubMed Abstract | Publisher Full Text 7. SPS3 Study Group, Benavente OR, Coffey CS, et al. : Blood-Pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013; 382 (9891): 507–517. PubMed Abstract | Publisher Full Text | Free Full Text 8. Mant J, McManus RJ, Roalfe A, et al. : Different Systolic Blood Pressure targets for people with history of stroke or Transient Ischaemic Attack: PAST-BP (Prevention After Stroke—Blood Pressure) randomised controlled trial. BMJ. 2016; 352 : i708. PubMed Abstract | Publisher Full Text | Free Full Text 9. Kitagawa K, Yamamoto Y, Arima H, et al. : Effect of standard vs intensive Blood Pressure control on the risk of recurrent stroke: a randomized clinical trial and meta-analysis. JAMA Neurol. 2019; 76 (11): 1309–1318. PubMed Abstract | Publisher Full Text | Free Full Text 10. Dawson J, Béjot Y, Christensen LM, et al. : European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or Transient Ischaemic Attack. Eur Stroke J. 2022; 7 (3): I–II. PubMed Abstract | Publisher Full Text | Free Full Text 11. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. : 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline from the American Heart Association/American Stroke Association. Stroke. 2021; 52 (7): e364–e467. PubMed Abstract | Publisher Full Text 12. Intercollegiate Stroke Working Party: National Clinical Guideline for Stroke for the UK and Ireland. Intercollegiate Stroke Working Party, 2023. Reference Source 13. Doogue R, McCann D, Fitzgerald N, et al. : Blood pressure control in patients with a previous stroke/Transient Ischaemic Attack in primary care in Ireland: a cross sectional study. BMC Fam Pract. 2020; 21 (1): 139. PubMed Abstract | Publisher Full Text | Free Full Text 14. Brewer L, Mellon L, Hall P, et al. : Secondary prevention after ischaemic stroke: the ASPIRE-S study. BMC Neurol. 2015; 15 (1): 216. PubMed Abstract | Publisher Full Text | Free Full Text 15. Heuschmann PU, Kircher J, Nowe T, et al. : Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Prev Cardiol. 2015; 22 (10): 1354–1362. PubMed Abstract | Publisher Full Text 16. McManus RJ, Mant J, Haque MS, et al. : Effect of self-monitoring and medication self-titration on Systolic Blood Pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014; 312 (8): 799–808. PubMed Abstract | Publisher Full Text 17. McManus RJ, Mant J, Franssen M, et al. : Efficacy of self-monitored Blood Pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018; 391 (10124): 949–959. PubMed Abstract | Publisher Full Text | Free Full Text 18. Eldridge SM, Lancaster GA, Campbell MJ, et al. : Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS One. 2016; 11 (3): e0150205. PubMed Abstract | Publisher Full Text | Free Full Text 19. Sheppard JP, Tucker KL, Davison WJ, et al. : Self-monitoring of Blood Pressure in patients with hypertension-related multi-morbidity: Systematic review and individual patient data meta-analysis. Am J Hypertens. 2020; 33 (3): 243–251. PubMed Abstract | Publisher Full Text | Free Full Text 20. Doogue R, Hayes P, Hebert R, et al. : Towards an integrated Blood Pressure self-monitoring solution for stroke/TIA in Ireland: a mixed methods feasibility study for the TASMIN5S IRL randomised controlled trial. Pilot Feasibility Stud. 2023; 9 (1): 9. PubMed Abstract | Publisher Full Text | Free Full Text 21. Naqvi IA, Strobino K, Kuen Cheung Y, et al. : Telehealth After Stroke Care pilot randomized trial of home Blood Pressure telemonitoring in an underserved setting. Stroke. 2022; 53 (12): 3538–3547. PubMed Abstract | Publisher Full Text | Free Full Text 22. Ogedegbe G, Teresi JA, Williams SK, et al. : Home Blood Pressure telemonitoring and nurse case management in black and hispanic patients with stroke: a randomized clinical trial. JAMA. 2024; 332 (1): 41–50. PubMed Abstract | Publisher Full Text | Free Full Text 23. Synnott P, Kelly PJ: Spirit Checklist. [Dataset]. Zenodo.2025. https://zenodo.org/records/17419006 Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 16 Dec 2025 ADD YOUR COMMENT Comment Author details Author details 1 Health Research Board (HRB), Stroke Clinical Trials Network Ireland (SCTNI), Dublin, Ireland 2 University College Dublin School of Medicine, Dublin, Leinster, Ireland 3 Stroke Service, Mater Misericordiae University Hospital, Dublin, Leinster, Ireland 4 Department of Geriatric Medicine, Cork University Hospital, Cork, County Cork, Ireland 5 Insight Centre for Data Analytics, University College Dublin, Dublin, Leinster, Ireland 6 Royal College of Surgeons in Ireland Faculty of Medicine and Health Sciences, Dublin, Leinster, Ireland 7 Department of Stroke Medicine, Beaumont Hospital, Dublin, Leinster, Ireland 8 Department of Geriatric and Stroke Medicine, Tallaght University Hospital, Dublin, Leinster, Ireland 9 Department of Geriatric Medicine, St Vincent's University Hospital, Dublin, Leinster, Ireland 10 Department of Neurology, St James's Hospital, Dublin, Leinster, Ireland Pádraig Synnott Roles: Investigation, Writing – Original Draft Preparation, Writing – Review & Editing Kirstyn James Roles: Writing – Review & Editing Brian Caulfield Roles: Writing – Review & Editing Catherine Lynch Roles: Project Administration, Writing – Review & Editing Katrina Tobin Roles: Project Administration, Writing – Review & Editing John J McCabe Roles: Writing – Review & Editing Michael Marnane Roles: Writing – Review & Editing Peter Megyesi Roles: Writing – Review & Editing David J Williams Roles: Writing – Review & Editing Sarah Coveney Roles: Writing – Review & Editing Derek Hayden Roles: Writing – Review & Editing Tim Cassidy Roles: Writing – Review & Editing David Bradley Roles: Writing – Review & Editing Peter J Kelly Roles: Conceptualization, Funding Acquisition, Methodology, Supervision, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information Health Research Board [DIFA-2020-015] The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (1) version 1 Published: 16 Dec 2025, 8:131 https://doi.org/10.12688/hrbopenres.14281.1 Copyright © 2025 Synnott P et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics VIEWS $counts.viewCount downloads Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Synnott P, James K, Caulfield B et al. Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] . HRB Open Res 2025, 8 :131 ( https://doi.org/10.12688/hrbopenres.14281.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 16 Dec 2025 Views 0 Cite How to cite this report: Ishiguchi H. Reviewer Report For: Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] . HRB Open Res 2025, 8 :131 ( https://doi.org/10.21956/hrbopenres.15711.r52281 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-131/v1#referee-response-52281 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 13 Jan 2026 Hironori Ishiguchi , Yamaguchi University, Yamaguchi, Yamaguchi Prefecture, Japan Approved with Reservations VIEWS 0 https://doi.org/10.21956/hrbopenres.15711.r52281 This manuscript describes the EPICS-Pilot trial, a multicentre PROBE randomised pilot/feasibility study in Ireland evaluating home blood pressure monitoring with telemonitoring (HBPM-TM) and early medication titration versus usual care after ischaemic stroke/high-risk TIA. The protocol is well structured, clinically ... Continue reading READ ALL This manuscript describes the EPICS-Pilot trial, a multicentre PROBE randomised pilot/feasibility study in Ireland evaluating home blood pressure monitoring with telemonitoring (HBPM-TM) and early medication titration versus usual care after ischaemic stroke/high-risk TIA. The protocol is well structured, clinically relevant, and addresses an important evidence-to-practice gap in achieving guideline SBP targets. ＃１．The intervention is driven by home BP data, yet the primary outcome is office SBP at 3 months. Please strengthen the rationale for choosing office SBP as the primary endpoint and provide additional detail on standardisation/blinding of office BP measurement across sites (device, operator training, rest period, number of readings, and procedures to maintain assessor blinding). ＃２．The control arm may include office BP, ABPM, or HBPM, which could dilute between-group differences and complicate interpretation. Please specify how out-of-office BP monitoring in the control arm will be documented, and consider a pre-specified sensitivity analysis accounting for HBPM/ABPM use in controls. ＃３．This wide window (72hour to 1 year) may introduce substantial heterogeneity in BP trajectories, care pathways, and recurrence risk. Please clarify whether randomisation will be stratified by time since event (beyond minimisation) and consider pre-specified exploratory subgroup analyses (e.g., early vs late post-event) to support interpretation. ＃４．Comparing mean SBP at 3 months by t-test is acceptable for a pilot, but an ANCOVA model adjusting for baseline SBP and minimisation variables would generally improve precision and interpretability. Please clarify the intended estimand (ITT) and how missing data will be handled. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? No Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Stroke, Thrombosis, Atrial Fibrillation I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Ishiguchi H. Reviewer Report For: Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] . HRB Open Res 2025, 8 :131 ( https://doi.org/10.21956/hrbopenres.15711.r52281 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-131/v1#referee-response-52281 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 16 Dec 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 Version 1 16 Dec 25 read Hironori Ishiguchi , Yamaguchi University, Yamaguchi, Japan Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2026 Ishiguchi H. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 13 Jan 2026 | for Version 1 Hironori Ishiguchi , Yamaguchi University, Yamaguchi, Yamaguchi Prefecture, Japan 0 Views copyright © 2026 Ishiguchi H. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions This manuscript describes the EPICS-Pilot trial, a multicentre PROBE randomised pilot/feasibility study in Ireland evaluating home blood pressure monitoring with telemonitoring (HBPM-TM) and early medication titration versus usual care after ischaemic stroke/high-risk TIA. The protocol is well structured, clinically relevant, and addresses an important evidence-to-practice gap in achieving guideline SBP targets. ＃１．The intervention is driven by home BP data, yet the primary outcome is office SBP at 3 months. Please strengthen the rationale for choosing office SBP as the primary endpoint and provide additional detail on standardisation/blinding of office BP measurement across sites (device, operator training, rest period, number of readings, and procedures to maintain assessor blinding). ＃２．The control arm may include office BP, ABPM, or HBPM, which could dilute between-group differences and complicate interpretation. Please specify how out-of-office BP monitoring in the control arm will be documented, and consider a pre-specified sensitivity analysis accounting for HBPM/ABPM use in controls. ＃３．This wide window (72hour to 1 year) may introduce substantial heterogeneity in BP trajectories, care pathways, and recurrence risk. Please clarify whether randomisation will be stratified by time since event (beyond minimisation) and consider pre-specified exploratory subgroup analyses (e.g., early vs late post-event) to support interpretation. ＃４．Comparing mean SBP at 3 months by t-test is acceptable for a pilot, but an ANCOVA model adjusting for baseline SBP and minimisation variables would generally improve precision and interpretability. Please clarify the intended estimand (ITT) and how missing data will be handled. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? No Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Stroke, Thrombosis, Atrial Fibrillation I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Ishiguchi H. Peer Review Report For: Home blood pressure measurement, telemonitoring and medication titration for secondary prevention of ischaemic stroke: study protocol for a PROBE randomised controlled pilot and feasibility study [version 1; peer review: 1 approved with reservations] . HRB Open Res 2025, 8 :131 ( https://doi.org/10.21956/hrbopenres.15711.r52281) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-131/v1#referee-response-52281 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with HRB Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Home blood pressure measurement, telemonitoring...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://hrbopenresearch.org/articles/8-131/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://hrbopenresearch.org/articles/8-131/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://hrbopenresearch.org/articles/8-131/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Synnott P et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://hrbopenresearch.org/articles/8-131/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://hrbopenresearch.org/articles/8-131", templates : { twitter : "Home blood pressure measurement, telemonitoring and medication.... Synnott P et al., published by " + "@HRBOpenRes" + ", https://hrbopenresearch.org/articles/8-131/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/14281/15711") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "15711"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "52779": 0, "52780": 0, "52781": 0, "52782": 0, "52783": 0, "52784": 0, "52785": 0, "52273": 0, "52786": 0, "52274": 0, "52787": 0, "52275": 0, "52788": 0, "52276": 0, "52277": 0, "52278": 0, "52279": 0, "52280": 0, "52281": 6, "52282": 0, "52556": 0, "53324": 0, "52557": 0, "53325": 0, "52558": 0, "53326": 0, "52559": 0, "53327": 0, "52560": 0, "53328": 0, "52561": 0, "53329": 0, "52562": 0, "53330": 0, "52563": 0, "53331": 0, "52564": 0, "53332": 0, "52565": 0, "53333": 0, "52971": 0, "52972": 0, "52973": 0, "52974": 0, "52975": 0, "52976": 0, "52977": 0, "52978": 0, "52979": 0, "52980": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "4445d806-cb62-4eb2-aa8e-557618713a58"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a HRB-funded researcher? Submission to HRB Open Research is open to all HRB grantholders or people working on a HRB-funded/co-funded grant on or since 1 January 2017. Sign up for information about developments, publishing and publications from HRB Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to HRB Open Research HRB Open Research Browse How to Publish About Contact RSS Cookie Notice Privacy Notice Legal Submit Your Research © F1000 Research Limited and its licensors ISSN 2515-4826 | Legal background var F1000platform = new F1000.Platform({ name: "hrb", displayName: "HRB Open Research", hostName: "hrbopenresearch.org", id: "5", editorialEmail: "[email protected]", infoEmail: "[email protected]" }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); }); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a026f15e0cf352ad',t:'MTc3OTkwNTA3NA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();